Modicus Prime Raises $3.5M for Commercial Production Quality Control

As Modicus Prime continues to build AI alliances within the pharmaceutical sector, its growth trajectory is attracting exceptional venture partners. The company extends a warm welcome to the newest members of its investor community.

Modicus Prime is excited to announce its recent investment from Silverton Partners, with additional support from Alumni Ventures and other top venture firms. This funding follows the successful implementation of the company’s AI quality control software, mpVision, across various global pharmaceutical companies, CMOs, and CDMOs producing biologics, cell and gene therapies, and vaccines.

Modicus Prime thanks all its investors who have played a crucial role in its success.

For more details about Modicus Prime’s AI cloud technology for pharma, read the PR Newswire press release.

About Modicus Prime

Modicus Prime’s computer vision software automates biologics image analysis and is designed to solve for the cost, legal, and waste liabilities from product quality failures across R&D and manufacturing.  A resident of Johnson & Johnson’s JLABS at the Texas Medical Center, Modicus Prime is venture-backed and has strategic partnerships with organizations including Takeda Pharmaceuticals, Oak Ridge National Laboratory (DOE), Dotmatics, eLabNext (Eppendorf), and PlugandPlay Health. Current implementation areas for the software include biologics, cell and gene therapies (including AAV manufacturing), and vaccines for pharmaceutical manufacturing, CMOs, CDMOs, and CROs.